Normal
Pharmaceutical distribution, especially the generic products, might be one of those markets where the margins are so low that the existing distribution channels and contractual/compliance channels of incumbents such as SIP provide a sufficient defensive moat. With the massive destruction of shareholder value that occurred in the GFC I've never looked into SIP but it could be a defensive income earner?
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
